AOPs

OECD View API
Toggle for API info
The API endpoint defaults to 25 results per page, but you can adjust this by changing the per_page parameter in the URL.
Searches both title and fulltext content
Takes you to the requested AOP
Clear Search Terms Clears search terms and filters

Showing 51 to 75 of 558 AOPs

Clear Table Filters
ID Title Point of Contact License MIE AO OECD Status OECD Project
111 Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) Charles Wood BY-SA 1614: Decrease, androgen receptor activation 745: Increase, Leydig cell tumors
110 Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) Charles Wood BY-SA 424: Inhibition, Na+/I- symporter (NIS) 741: Increase, Adenomas/carcinomas (follicular cell)
109 Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) Charles Wood BY-SA 770: Increase, Cytotoxicity (club cells) 736: Increase, Adenomas/carcinomas (bronchioloalveolar)
108 Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) Charles Wood BY-SA 724: Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme 719: Increase, hepatocellular adenomas and carcinomas
105 Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) Charles Wood BY-SA 714: Increased, Binding of chemicals to 2u (serum) 713: Increase, Adenomas/carcinomas (renal tubular)
117 Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) Charles Wood Open for adoption 25: Agonism, Androgen receptor 719: Increase, hepatocellular adenomas and carcinomas Under Development 1.26
538 Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways Yanhong Wei BY-SA None 2161: Increase, Vascular disrupting effects
509 Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction Yanhong Wei BY-SA 1417: NFE2/Nrf2 repression 2161: Increase, Vascular disrupting effects
510 Demethylation of PPAR promotor leading to vascular disrupting effects Yanhong Wei BY-SA 228: peroxisome proliferator activated receptor promoter demethylation 2161: Increase, Vascular disrupting effects
511 The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects Yanhong Wei BY-SA 1115: Increase, Reactive oxygen species 2161: Increase, Vascular disrupting effects
507 Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway Yanhong Wei BY-SA 1417: NFE2/Nrf2 repression 2161: Increase, Vascular disrupting effects
508 Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway Yanhong Wei BY-SA 1417: NFE2/Nrf2 repression 2161: Increase, Vascular disrupting effects
220 Cyp2E1 Activation Leading to Liver Cancer Francina Webster BY-SA 1391: Activation of Cyp2E1 1395: Liver Cancer WPHA/WNT Endorsed 1.24
579 Transthyretin disruption in developing fish leading to projected decline in fish population Adriana Webb BY-SA None None
281 Acetylcholinesterase Inhibition Leading to Neurodegeneration Karen Watanabe BY-SA 12: Acetylcholinesterase (AchE) Inhibition 352: N/A, Neurodegeneration
431 Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) Qi Wang BY-SA 1950: Increase, TNF 1953: Gestational diabetes mellitus
278 IKK complex inhibition leading to liver injury Nanette Vrijenhoek BY-SA 1574: Inhibition, IKK complex
237 Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response Ulla Vogel BY-SA 1495: Substance interaction with the lung resident cell membrane components 1443: Atherosclerosis Under Development 1.55
503 Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation Barbara Viviani BY-SA 1065: Activation, estrogen receptor alpha 2154: Uterine adenocarcinoma (endometrioid adenocarcinoma Type I) Under Review 1.100
587 Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits Barbara Viviani BY-SA 1542: Inhibition, Mitochondrial complex III 896: Parkinsonian motor deficits
588 Inhibition of the mitochondrial complex II of nigro-striatal neurons leads to parkinsonian motor deficits Barbara Viviani BY-SA 2118: Succinate dehydrogenase, inhibited 896: Parkinsonian motor deficits
589 Inhibition of the mitochondrial complex IV of nigro-striatal neurons leads to parkinsonian motor deficits Barbara Viviani BY-SA 1543: Mitochondrial Complex IV inhibition 896: Parkinsonian motor deficits
27 Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) Mathieu Vinken BY-SA 41: Inhibition, Bile Salt Export Pump (ABCB11) 357: Cholestasis, Pathology Under Development 1.19
205 AOP from chemical insult to cell death Mathieu Vinken BY-SA
211 Handbook development AOP Dan Villeneuve BY-SA None None